iBio, Inc. (IBIO)
About iBio, Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $400.0K
- Net income
- -$18.4M
- Total assets
- $23.2M
- Market cap
- $71.0M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $71.0M
- Shares outstanding
- 98.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 19, 2008
iBio, Inc. (IBIO) Stock Price
- Reported a net loss of $18.4M in FY2025.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review iBio, Inc..
Write a review
News about iBio, Inc.
News & sentiment via Polygon.io
iBio, Inc.: frequently asked questions
Is iBio, Inc. an American company?
iBio, Inc. is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is iBio, Inc. headquartered?
iBio, Inc. is headquartered in New York, New York, United States.
Is iBio, Inc. publicly traded?
Yes — iBio, Inc. is a publicly traded company. Its stock trades under the ticker symbol IBIO on the NASDAQ.
What does iBio, Inc. do?
iBio, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
